230 related articles for article (PubMed ID: 18255056)
1. Involvement of vasopressin in affective disorders.
Surget A; Belzung C
Eur J Pharmacol; 2008 Apr; 583(2-3):340-9. PubMed ID: 18255056
[TBL] [Abstract][Full Text] [Related]
2. Stress responsive neurohormones in depression and anxiety.
Ströhle A; Holsboer F
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
[TBL] [Abstract][Full Text] [Related]
3. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
Ströhle A
Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
[TBL] [Abstract][Full Text] [Related]
4. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
Keck ME
Amino Acids; 2006 Oct; 31(3):241-50. PubMed ID: 16733617
[TBL] [Abstract][Full Text] [Related]
5. Mice selected for high versus low stress reactivity: a new animal model for affective disorders.
Touma C; Bunck M; Glasl L; Nussbaumer M; Palme R; Stein H; Wolferstätter M; Zeh R; Zimbelmann M; Holsboer F; Landgraf R
Psychoneuroendocrinology; 2008 Jul; 33(6):839-62. PubMed ID: 18502051
[TBL] [Abstract][Full Text] [Related]
6. The role of vasopressin in chronic stress studied in a chronic mild stress model of depression.
Zelena D; Domokos A; Barna I; Csabail K; Bagdy G; Makara GB
Ideggyogy Sz; 2007 Mar; 60(3-4):196-200. PubMed ID: 17451068
[TBL] [Abstract][Full Text] [Related]
7. Do anxiety and depression have a common pathophysiological mechanism?
Boyer P
Acta Psychiatr Scand Suppl; 2000; (406):24-9. PubMed ID: 11131467
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin in health and disease with a focus on affective disorders.
Zelena D
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
[TBL] [Abstract][Full Text] [Related]
9. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
Ressler KJ; Nemeroff CB
Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410
[TBL] [Abstract][Full Text] [Related]
10. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression.
van West D; Del-Favero J; Aulchenko Y; Oswald P; Souery D; Forsgren T; Sluijs S; Bel-Kacem S; Adolfsson R; Mendlewicz J; Van Duijn C; Deboutte D; Van Broeckhoven C; Claes S
Mol Psychiatry; 2004 Mar; 9(3):287-92. PubMed ID: 15094789
[TBL] [Abstract][Full Text] [Related]
11. [Neurobiology and genetics of anxiety in an animal model].
Landgraf R
Nervenarzt; 2003 Mar; 74(3):274-8. PubMed ID: 12627244
[TBL] [Abstract][Full Text] [Related]
12. A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine.
Coplan JD; Pine DS; Papp LA; Gorman JM
Psychopharmacol Bull; 1997; 33(2):193-204. PubMed ID: 9230631
[No Abstract] [Full Text] [Related]
13. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats.
Mlynarik M; Zelena D; Bagdy G; Makara GB; Jezova D
Horm Behav; 2007 Mar; 51(3):395-405. PubMed ID: 17258216
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity.
Spiga F; Harrison LR; Wood S; Knight DM; MacSweeney CP; Thomson F; Craighead M; Lightman SL
J Endocrinol; 2009 Mar; 200(3):273-83. PubMed ID: 19008333
[TBL] [Abstract][Full Text] [Related]
15. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome.
Tanriverdi F; Karaca Z; Unluhizarci K; Kelestimur F
Stress; 2007 Mar; 10(1):13-25. PubMed ID: 17454963
[TBL] [Abstract][Full Text] [Related]
16. Characterization of central and peripheral components of the hypothalamus-pituitary-adrenal axis in the inbred Roman rat strains.
Carrasco J; Márquez C; Nadal R; Tobeña A; Fernández-Teruel A; Armario A
Psychoneuroendocrinology; 2008 May; 33(4):437-45. PubMed ID: 18276081
[TBL] [Abstract][Full Text] [Related]
17. Dex/CRH-test response and sleep in depressed patients and healthy controls with and without vulnerability for affective disorders.
Friess E; Schmid D; Modell S; Brunner H; Lauer CJ; Holsboer F; Ising M
J Psychiatr Res; 2008 Oct; 42(14):1154-62. PubMed ID: 18281062
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
19. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
Goncharova ND; Chigarova OA; Oganyan TE
Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
[TBL] [Abstract][Full Text] [Related]
20. Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation.
Goekoop JG; de Winter RP; de Rijk R; Zwinderman KH; Frankhuijzen-Sierevogel A; Wiegant VM
Psychiatry Res; 2006 Feb; 141(2):201-11. PubMed ID: 16436301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
